Wai Yuen Tong Medicine Holdings Ltd revenue jumped on 106% in 2015 and EBITDA Margin decreased slightly on 0.51 pp from -5.0% to -5.5%
30/06/2015 • About Wai Yuen Tong Medicine Holdings Ltd (
$897) • By InTwits
Wai Yuen Tong Medicine Holdings Ltd reported FY2015 financial results today. Overall the company's long term financial model is characterised by the following facts:
- Wai Yuen Tong Medicine Holdings Ltd doesn't have a profitable business model yet: FY2015 ROIC is -37.5%
- The company operates at negative EBITDA Margin: -5.5%
- EBITDA Margin is quite volatile: -5.5% in FY2015, -5.0% in FY2014, 2.7% in FY2013, 4.7% in FY2012, 9.9% in FY2011
- Wai Yuen Tong Medicine Holdings Ltd motivates its personel by high Stock Based Compensation (SBC): average SBC/Revenue for FY2011-FY2015 was 0.0%. On average EBITDA Margin was -0.2% for the sames years0
- Wai Yuen Tong Medicine Holdings Ltd has low CAPEX intensity: 5 year average CAPEX/Revenue was 1.3%. At the same time it's a lot of higher than industry average of 4.7%.
- CAPEX is quite volatile: 31.8 in FY2015, 8.5 in FY2014, 6.1 in FY2013, 4.1 in FY2012, 19.7 in FY2011
- The company has unprofitable business model: ROIC is at -37.5%
- It operates with high leverage: Net Debt/EBITDA is 3.5x while industry average is 0.3x
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
Wai Yuen Tong Medicine Holdings Ltd ($897) key annual financial indicators
| mln. HKD | 2011 | 2012 | 2013 | 2014 | 2015 | 2015/2014 |
|---|
P&L
|
|---|
| Revenue | 735 | 662 | 965 | 864 | 1,776 | 105.6% |
| Gross Profit | 110 | 89 | 71 | 22 | -23 | -203.5% |
| SG&A | | | | | 88 | |
| EBITDA | 73 | 31 | 26 | -43 | -98 | 126.4% |
| Net Income | 55 | 33 | 26 | -48 | -117 | 142.7% |
Balance Sheet
|
|---|
| Cash | 65 | 66 | 50 | 267 | 189 | -29.4% |
| Short Term Debt | 79 | 67 | 49 | 3 | 33 | 874.5% |
| Long Term Debt | 0 | 0 | 0 | 178 | 174 | -2.0% |
Cash flow
|
|---|
| Capex | 20 | 4 | 6 | 9 | 32 | 273.7% |
Ratios
|
|---|
| Revenue growth | 15.4% | -9.9% | 45.9% | -10.5% | 105.6% | |
| EBITDA growth | 45.5% | -57.6% | -15.8% | -266.4% | 126.4% | |
| Gross Margin | 15.0% | 13.5% | 7.4% | 2.5% | -1.3% | -3.8% |
| EBITDA Margin | 9.9% | 4.7% | 2.7% | -5.0% | -5.5% | -0.5% |
| Net Income Margin | 7.5% | 5.0% | 2.7% | -5.6% | -6.6% | -1.0% |
| SG&A, % of revenue | | | | | 4.9% | 4.9% |
| CAPEX, % of revenue | 2.7% | 0.6% | 0.6% | 1.0% | 1.8% | 0.8% |
| ROIC | 38.0% | 13.6% | 9.3% | -16.9% | -37.5% | -20.6% |
| ROE | 50.2% | 24.9% | 13.8% | -28.2% | -137.3% | -109.2% |
| Net Debt/EBITDA | 0.2x | 0.0x | -0.1x | | | 0.0x |
Revenue and profitability
Wai Yuen Tong Medicine Holdings Ltd's Revenue surged on 106% in FY2015. Having declining revenue the company managed to increase EBITDA margin. EBITDA Margin increased on 4.2 pp from 18.0% to 22.2% in 2015.
Gross Margin decreased on 3.8 pp from 2.5% to -1.3% in FY2015.
Net Income marign decreased slightly on 1.0 pp from -5.6% to -6.6% in FY2015.
Capital expenditures (CAPEX) and working capital investments
In FY2015 the company had CAPEX/Revenue of 1.8%. The company showed small growth in CAPEX/Revenue of 1.2 pp from 0.62% in FY2012 to 1.8% in FY2015. Average CAPEX/Revenue for the last three years was 1.1%.
Return on investment
The company operates at negative ROIC (-37.54%) and ROE (-137.34%). ROIC dropped on 20.6 pp from -16.9% to -37.5% in FY2015. ROE dropped on 109 pp from -28.2% to -137% in FY2015.
Leverage (Debt)
Company's Net Debt / EBITDA is 3.5x and Debt / EBITDA is . Net Debt / EBITDA didn't change in FY2015. Debt surged on 14.4% in FY2015 while cash dropped on 29.4% in FY2015.
Appendix 1: Peers in Pharmaceuticals
Below we provide Wai Yuen Tong Medicine Holdings Ltd benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Hong Kong Life Sciences and Technology Group Ltd ($8085) | | -10.0% | -45.4% | 1,636.5% | -52.9% |
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | -17.7% | 15.1% | -99.9% | 480.0% | |
| United Gene High-Tech Group Ltd ($399) | | -71.8% | -60.5% | 196.0% | 14.2% |
| China Traditional Chinese Medicine Co Ltd ($570) | 3.1% | 22.3% | 35.2% | 90.0% | |
| Dragonite International Ltd ($329) | -8.8% | -10.5% | 13.5% | 64.8% | |
| |
|---|
| Median (38 companies) | 18.0% | 14.3% | 13.5% | 16.3% | -43.6% |
|---|
| Wai Yuen Tong Medicine Holdings Ltd ($897) | | -9.9% | 45.9% | -10.5% | 105.6% |
Top companies by Gross margin, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 83.9% | 82.0% | 81.5% | 80.9% | |
| Consun Pharmaceutical Group Ltd ($1681) | 75.5% | 75.7% | 79.1% | 78.3% | |
| Sino Biopharmaceutical Ltd ($1177) | 78.5% | 78.5% | 77.5% | 76.4% | |
| China Health Group Inc ($8225) | 38.7% | 43.4% | 33.6% | 76.2% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 72.6% | 65.2% | 77.9% | 72.1% | |
| |
|---|
| Median (36 companies) | 38.0% | 39.1% | 37.2% | 48.7% | 39.6% |
|---|
| Wai Yuen Tong Medicine Holdings Ltd ($897) | 15.0% | 13.5% | 7.4% | 2.5% | -1.3% |
Top companies by EBITDA margin, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Asia Resources Holdings Ltd ($899) | 3.5% | -80.8% | 25.1% | 113.7% | |
| Pak Fah Yeow International Ltd ($239) | 28.7% | 33.9% | 28.4% | 52.4% | |
| Real Nutriceutical Group Ltd ($2010) | 45.6% | 42.8% | 43.4% | 46.0% | |
| China Shineway Pharmaceutical Group Ltd ($2877) | 47.8% | 37.8% | 40.1% | 40.5% | |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 6.2% | 21.5% | 35.9% | 38.9% | |
| |
|---|
| Median (37 companies) | 17.4% | 19.6% | 18.8% | 20.8% | -8.9% |
|---|
| Wai Yuen Tong Medicine Holdings Ltd ($897) | 9.9% | 4.7% | 2.7% | -5.0% | -5.5% |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 0.2% | | 11,100.0% | 103.4% | |
| Extrawell Pharmaceutical Holdings Ltd ($858) | 5.7% | 1.7% | 20.6% | 92.4% | 3.6% |
| Asia Resources Holdings Ltd ($899) | 12.2% | 4.4% | 8.1% | 92.0% | |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 19.5% | 16.8% | 52.4% | 39.6% | |
| Hao Wen Holdings Ltd ($8019) | 6.4% | 30.0% | 2.3% | 38.2% | |
| |
|---|
| Median (37 companies) | 10.3% | 8.3% | 8.1% | 7.4% | 3.6% |
|---|
| Wai Yuen Tong Medicine Holdings Ltd ($897) | 2.7% | 0.6% | 0.6% | 1.0% | 1.8% |
Top companies by ROIC, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 18.5% | 16.7% | 20.8% | 33.0% | |
| Sino Biopharmaceutical Ltd ($1177) | 19.9% | 26.2% | 26.8% | 26.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 31.3% | 26.1% | 22.0% | 22.4% | |
| Shandong Luoxin Pharmaceutical Group Stock Co Ltd ($8058) | 34.4% | 27.6% | 22.2% | 19.9% | |
| CSPC Pharmaceutical Group Ltd ($1093) | 9.9% | 14.5% | 12.8% | 18.1% | |
| |
|---|
| Median (38 companies) | 8.4% | 11.6% | 7.8% | 10.0% | -8.5% |
|---|
| Wai Yuen Tong Medicine Holdings Ltd ($897) | 38.0% | 13.6% | 9.3% | -16.9% | -37.5% |
Top companies by Net Debt / EBITDA
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| China NT Pharma Group Co Ltd ($1011) | 0.4x | | | 7.2x | |
| United Laboratories International Holdings Ltd/The ($3933) | 4.4x | 6.5x | 4.6x | 4.2x | |
| Lansen Pharmaceutical Holdings Ltd ($503) | 0.9x | 1.7x | 2.8x | 3.4x | |
| China Grand Pharmaceutical and Healthcare Holdings Ltd ($512) | 2.5x | 5.4x | 4.0x | 3.4x | |
| Shandong Xinhua Pharmaceutical Co Ltd ($719) | 1.4x | 3.5x | 3.4x | 2.8x | |
| |
|---|
| Median (31 companies) | -0.4x | 0.1x | -0.1x | -0.5x | 9.9x |
|---|